Thank you

This live web event has ended. Thank you for attending.

Description

Detection of therapeutically targetable mutations in NSCLC: Is there a one size fits all cell free DNA test?

Why should you register now for this webinar?
Hear leading experts discuss the clinical applications of circulating cell free DNA (ccfDNA) in non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors or immune checkpoint inhibitors.
Brought to you by: CAP TODAY
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Presenters: Ed Schuuring, PhD, and Darryl Irwin, PhD

What will this webinar empower you to do?

• Understand the characteristics of a suitable diagnostic-grade platform required for the detection of tumor-specific mutations with high sensitivity in ccfDNA.
• Review the UltraSEEK^® Lung panel for the detection of the most common
  predictive markers in comparison to other circulating tumor DNA (ctDNA)
  detection assays for NSCLC.
• Appreciate the utility of ctDNA as a minimally invasive molecular tool to guide treatment decisions and disease monitoring, especially when no appropriate tumor tissue biopsy is available.
• Ask questions of our distinguished presenters